Organon (OGN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

OGN Stock Forecast


Organon stock forecast is as follows: an average price target of $24.00 (represents a 41.84% upside from OGN’s last price of $16.92) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

OGN Price Target


The average price target for Organon (OGN) is $24.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $24.00. This represents a potential 41.84% upside from OGN's last price of $16.92.

OGN Analyst Ratings


Buy

According to 3 Wall Street analysts, Organon's rating consensus is 'Buy'. The analyst rating breakdown for OGN stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Organon Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 29, 2024David AmsellemPiper Sandler$24.00$18.8427.35%41.84%
Jun 26, 2023David AmsellemPiper Sandler$34.00$20.3666.95%100.95%
Row per page
Go to

The latest Organon stock forecast, released on Apr 29, 2024 by David Amsellem from Piper Sandler, set a price target of $24.00, which represents a 27.35% increase from the stock price at the time of the forecast ($18.84), and a 41.84% increase from OGN last price ($16.92).

Organon Price Target by Period


1M3M12M
# Anlaysts--1
Avg Price Target--$24.00
Last Closing Price$16.92$16.92$16.92
Upside/Downside-100.00%-100.00%41.84%

In the current month, the average price target of Organon stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Organon's last price of $16.92. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Apr 29, 2024Piper SandlerOverweightOverweightHold
Mar 13, 2024Piper SandlerOverweightOverweightHold
Jan 12, 2024Piper SandlerOverweightOverweightHold
Dec 12, 2023Piper SandlerOverweightOverweightHold
Nov 09, 2023Piper SandlerOverweightOverweightHold
Jun 08, 2023Morgan StanleyEqual-WeightEqual-WeightHold
May 09, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Sep 06, 2022Piper Sandler-OverweightUpgrade
Apr 27, 2022Goldman Sachs-BuyInitialise
Feb 22, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Row per page
Go to

Organon's last stock rating was published by Piper Sandler on Apr 29, 2024. The company gave OGN a "Overweight" rating, the same as its previous rate.

Organon Financial Forecast


Organon Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
Revenue--------$1.60B$1.52M$1.61M$1.54B$1.49B$1.54B$1.58B$1.57B$1.60B$1.60B$1.59B$1.51B
Avg Forecast$1.58B$1.57B$1.61B$1.60B$1.59B$1.56B$1.61B$1.57B$1.55B$1.57B$1.57B$1.54B$1.49B$1.51B$1.53B$1.52B$1.57B$1.58B$1.52B$1.57B
High Forecast$1.60B$1.59B$1.62B$1.62B$1.61B$1.56B$1.61B$1.57B$1.59B$1.60B$1.58B$1.56B$1.51B$1.51B$1.53B$1.52B$1.57B$1.58B$1.52B$1.57B
Low Forecast$1.57B$1.55B$1.59B$1.59B$1.58B$1.56B$1.61B$1.56B$1.52B$1.56B$1.55B$1.53B$1.48B$1.51B$1.53B$1.52B$1.57B$1.58B$1.52B$1.57B
# Analysts11114211354433334444
Surprise %--------1.03%0.00%0.00%1.00%0.99%1.02%1.03%1.03%1.02%1.01%1.05%0.96%

Organon's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.57B, with a low forecast of $1.56B, and a high forecast of $1.57B. OGN's average Quarter revenue forecast represents a -2.05% decrease compared to the company's last Quarter revenue of $1.60B (Dec 23).

Organon EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts11114211354433334444
EBITDA--------$370.00M$232.00K$389.00K$388.00M$279.00M$415.00M$482.00M$539.00M$396.00M$539.00M$538.00M$509.00M
Avg Forecast$544.49M$540.07M$553.02M$551.27M$546.99M$537.44M$554.05M$692.28M$534.05M$540.97M$537.88M$547.26M$393.78M$520.33M$526.71M$432.62M$540.61M$543.51M$454.95M$539.18M
High Forecast$549.21M$544.76M$557.82M$556.06M$551.73M$537.79M$554.05M$830.74M$547.83M$550.19M$542.55M$656.71M$472.54M$520.33M$526.71M$519.14M$540.61M$543.51M$545.94M$539.18M
Low Forecast$538.57M$534.20M$547.01M$545.28M$543.48M$537.09M$554.05M$553.83M$523.71M$535.48M$532.03M$437.81M$315.03M$520.33M$526.71M$346.09M$540.61M$543.51M$363.96M$539.18M
Surprise %--------0.69%0.00%0.00%0.71%0.71%0.80%0.92%1.25%0.73%0.99%1.18%0.94%

1 analysts predict OGN's average Quarter EBITDA for Mar 24 to be $692.28M, with a high of $830.74M and a low of $553.83M. This is 87.10% upper than Organon's previous annual EBITDA (Dec 23) of $370.00M.

Organon Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts11114211354433334444
Net Income--------$546.00M$58.00K$242.00K$177.00M$108.00M$227.00M$234.00M$348.00M$202.00M$323.00M$427.00M$399.00M
Avg Forecast$261.49M$250.23M$266.90M$267.55M$240.46M$234.67M$279.39M$406.95M$210.66M$272.81M$252.66M$321.70M$200.87M$284.83M$303.30M$254.31M$321.42M$372.32M$361.09M$447.37M
High Forecast$264.44M$253.06M$269.91M$270.57M$247.82M$246.70M$279.44M$488.34M$281.76M$280.46M$255.51M$386.04M$241.04M$284.83M$305.66M$305.17M$321.42M$372.32M$433.30M$447.37M
Low Forecast$257.79M$246.69M$263.13M$263.77M$230.65M$222.65M$279.33M$325.56M$179.06M$265.16M$249.08M$257.36M$160.70M$284.83M$300.94M$203.45M$321.42M$372.32M$288.87M$447.37M
Surprise %--------2.59%0.00%0.00%0.55%0.54%0.80%0.77%1.37%0.63%0.87%1.18%0.89%

Organon's average Quarter net income forecast for Mar 24 is $406.95M, with a range of $325.56M to $488.34M. OGN's average Quarter net income forecast represents a -25.47% decrease compared to the company's last Quarter net income of $546.00M (Dec 23).

Organon SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts11114211354433334444
SG&A--------$469.00M$538.00K$451.00K$435.00M$470.00M$440.00M$423.00M$371.00M$482.00M$388.00M$416.00M$382.00M
Avg Forecast$391.10M$387.92M$397.22M$395.97M$392.89M$386.03M$397.97M$433.85M$383.60M$388.57M$386.35M$342.96M$479.30M$373.75M$378.33M$271.12M$388.31M$390.39M$351.79M$387.28M
High Forecast$394.49M$391.29M$400.67M$399.40M$396.30M$386.28M$397.97M$520.61M$393.50M$395.19M$389.71M$411.55M$575.16M$373.75M$378.33M$325.34M$388.31M$390.39M$422.14M$387.28M
Low Forecast$386.84M$383.71M$392.91M$391.66M$390.37M$385.78M$397.97M$347.08M$376.17M$384.62M$382.15M$274.37M$383.44M$373.75M$378.33M$216.89M$388.31M$390.39M$281.43M$387.28M
Surprise %--------1.22%0.00%0.00%1.27%0.98%1.18%1.12%1.37%1.24%0.99%1.18%0.99%

Organon's average Quarter SG&A projection for Mar 24 is $433.85M, based on 1 Wall Street analysts, with a range of $347.08M to $520.61M. The forecast indicates a -7.50% fall compared to OGN last annual SG&A of $469.00M (Dec 23).

Organon EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
# Analysts11114211354433334444
EPS--------$2.13--$0.70$0.42$0.89$0.92$1.37$0.80$1.27$1.68$1.58
Avg Forecast$1.01$0.96$1.03$1.03$0.93$0.90$1.08$0.98$0.81$1.05$0.97$1.17$0.92$1.10$1.17$1.30$1.24$1.44$1.42$1.73
High Forecast$1.02$0.97$1.04$1.04$0.95$0.95$1.08$0.98$1.08$1.08$0.98$1.18$0.93$1.10$1.18$1.36$1.24$1.44$1.42$1.73
Low Forecast$0.99$0.95$1.01$1.02$0.89$0.86$1.08$0.98$0.69$1.02$0.96$1.15$0.91$1.10$1.16$1.24$1.24$1.44$1.42$1.73
Surprise %--------2.63%0.00%0.00%0.60%0.46%0.81%0.78%1.05%0.64%0.88%1.19%0.91%

According to 1 Wall Street analysts, Organon's projected average Quarter EPS for Mar 24 is $0.98, with a low estimate of $0.98 and a high estimate of $0.98. This represents a -54.09% decrease compared to OGN previous annual EPS of $2.13 (Dec 23).

Organon Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PFEPfizer$27.76$44.7661.24%Hold
BIIBBiogen$173.52$276.3859.28%Buy
OGNOrganon$16.92$24.0041.84%Buy
MRKMerck$101.87$129.4727.09%Buy
AZNAstraZeneca$71.43$84.3318.06%Buy
BMYBristol-Myers Squibb Company$55.45$64.5716.45%Hold
JNJJohnson & Johnson$158.24$179.1313.20%Buy
SNYSanofi$52.95$57.368.33%Buy
NVSNovartis$110.52$116.335.26%Hold
LLYEli Lilly and Company$806.14$782.65-2.91%Buy
AMGNAmgen$316.91$293.15-7.50%Buy
GILDGilead Sciences$89.84$81.32-9.48%Buy
ABBVAbbVie$200.47$174.04-13.18%Buy

OGN Forecast FAQ


Yes, according to 3 Wall Street analysts, Organon (OGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of OGN's total ratings.

Organon (OGN) average price target is $24 with a range of $24 to $24, implying a 41.84% from its last price of $16.92. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for OGN stock, the company can go up by 41.84% (from the last price of $16.92 to the average price target of $24), up by 41.84% based on the highest stock price target, and up by 41.84% based on the lowest stock price target.

OGN's average twelve months analyst stock price target of $24 does not support the claim that Organon can reach $30 in the near future.

Organon's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $6.33B (high $6.35B, low $6.32B), average EBITDA is $2.33B (high $2.47B, low $2.19B), average net income is $1.16B (high $1.26B, low $1.06B), average SG&A $1.61B (high $1.7B, low $1.52B), and average EPS is $3.88 (high $3.96, low $3.8). OGN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $6.37B (high $6.42B, low $6.3B), average EBITDA is $2.19B (high $2.21B, low $2.17B), average net income is $1.05B (high $1.06B, low $1.03B), average SG&A $1.57B (high $1.59B, low $1.56B), and average EPS is $4.03 (high $4.07, low $3.97).

Based on Organon's last annual report (Dec 2023), the company's revenue was $6.26B, beating the average analysts forecast of $6.24B by 0.43%. Apple's EBITDA was $1.55B, missing the average prediction of $2.16B by -28.11%. The company's net income was $1.02B, missing the average estimation of $1.06B by -3.29%. Apple's SG&A was $1.89B, beating the average forecast of $1.5B by 26.08%. Lastly, the company's EPS was $3.99, missing the average prediction of $4 by -0.24%. In terms of the last quarterly report (Dec 2023), Organon's revenue was $1.6B, beating the average analysts' forecast of $1.55B by 2.83%. The company's EBITDA was $370M, missing the average prediction of $534.05M by -30.72%. Organon's net income was $546M, beating the average estimation of $210.66M by 159.18%. The company's SG&A was $469M, beating the average forecast of $383.6M by 22.26%. Lastly, the company's EPS was $2.13, beating the average prediction of $0.811 by 162.64%